Nxstage Medical, Inc. (NXTM) Tops Q2 EPS by 1c; Guides Q3 EPS, Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Wells Fargo names 13 stocks as overweight tactical ideas
Lazard Capital Downgrades NxStage Medical (NXTM) to Neutral
July 26, 2013 8:36 AM EDTLazard Capital downgraded NxStage Medical (NASDAQ: NXTM) from Buy to Neutral.
For an analyst ratings summary and ratings history on NxStage Medical click here. For more ratings news on NxStage Medical click here.
Shares of NxStage Medical closed at $13.59 yesterday, with a 52 week range of $10.15-$16.25.... More
